AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06409962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological combination
Description: The intervention comprises workshops, individualized counseling, cooking classes, and physical activity promotion. It emphasizes nutritional education, hands-on cooking, and behavioral modification techniques. Participants receive personalized guidance and resources to make sustainable dietary and lifestyle changes. Social support networks foster motivation and accountability. By combining these components, the intervention aims to empower participants with the knowledge, skills, and support needed for long-term health improvements.
Study NCT06004102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminder text message
Description: The study aimed to assess the impact of text message reminders on medication adherence among kidney transplant recipients.
Study NCT06516419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concentrated secretome Injection 2mL
Description: The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.
Study NCT06516419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP.~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject~2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject
Study NCT06516419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Combination Cream
Description: 1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles~2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.
Study NCT06140810 — intervention group
Intervention type: OTHER
Intervention: Lung Recruitment
Description: Lung Recruitment will be performed during general anesthesia to reduce areas of atelectasis
Study NCT06149468 — intervention group
Intervention type: OTHER
Intervention: inclusion in the register
Description: socio-demographic data collection and proposed therapy
Study NCT04619771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
Study NCT05083585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based vaccine
Description: Ad26.RSV.preF-based vaccine will be administered as a single intramuscular injection.
Study NCT05226494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fb-PMT
Description: Daily dosing based on patient weight
Study NCT06327880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07054894 or placebo
Description: multiple oral doses of PF-07054894 for 14 days
Study NCT06327880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-07054894 or placebo
Description: multiple oral doses of PF-07054894 for 14 days
Study NCT04858022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Acoustic Biofeedback
Description: In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
Study NCT04858022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment - waitlist
Description: 10-week period of no treatment
Study NCT06522542 — intervention group
Intervention type: DRUG
Intervention: systematic therapy
Description: All patients received systematic therapy including chemotherapy, targeted therapy or immune checkpoint inhibitor. We aims to investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.
Study NCT06314828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RJMty19 (CD19-CAR-DNT cells)
Description: Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide, fludarabine and Etoposide lymphodepleting chemotherapy.
Study NCT06326333 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Combined parasternal block and serratus anterior plane block
Description: The first PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the second intercostal space.~The second PSB will be applied to the patients with 7.5 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the fourth intercostal space.~The SAPB will be applied to the patients with 10 ml of 0.25% bupivacaine under real-time ultrasound guidance at the level of the sixth rib in the anterior axillary line.~The block applications will be applied bilaterally.
Study NCT05925868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness app
Description: Parents will use the mindfulness app, Headspace, for at least 10 minutes on 4 days/week.
Study NCT06373133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: 1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w
Study NCT06373133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 1200mg, ivgtt, d1, q3w
Study NCT06373133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP102
Description: 7.5mg/kg, ivgtt, d1, q3w
Study NCT04240834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
Study NCT04240834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
Study NCT04240834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
Study NCT04240834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of 12 months of ticagrelor and low-dose aspirin versus 12 months of standard dual anti-platelet therapy (DAPT)
Study NCT04753151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
Study NCT04753151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The study will be designed as a prospective, double-blinded clinical trial, compared to placebo (0.9% saline) in combination with conventional treatment. Patients will receive intravenous administration of 10 mg / kg tranexamic acid or placebo (0.9% saline) for 10 minutes in the 20 minutes prior to the estimated skin incision. Right after the skin incision, a maintenance dose of 1 mg / kg / h of tranexamic acid (or equivalent infusion rate of 0.9% saline) will be started, remaining until the end of the suture of the surgical wound.
Study NCT02406534 — intervention group
Intervention type: BEHAVIORAL
Intervention: HRQoL surveys
Study NCT05386407 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: telemedically guided oropharyngeal + nasal (OP+N) self-sampling (GSS) and nasopharyngeal (NP) or OP+N sampling performed by health care professionals (HCP)
Description: After giving informed consent by signing the consent form, patients will be randomized to either OP+N GSS - or to OP+N USS.~After performing either procedure, they will continue to be sampled by HCP OP+N and HCP NP.
Study NCT06329895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Oral administration.
Study NCT06329895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Oral administration.
Study NCT06329895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral administration.
Study NCT05679895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD1a-CAR T
Description: Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
Study NCT05302336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
Description: All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide).
Study NCT05225805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Antibiotic
Study NCT04947982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon dioxide
Description: carbon dioxide insufflation pressure
Study NCT04723797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity program consisting of running and/or cycling
Study NCT06276504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
Description: Pembrolizumab administration at D0, M1 and M2
Study NCT04953728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA)
Description: Each participant will undergo 5 sessions total at two different frequencies (25 Hz and 100Hz) with electrodes placed at two different locations (wrist and knee) and a placebo session.
Study NCT05644522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
Description: The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
Study NCT05644522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
Description: The Nomad is a microprocessor-controlled knee-ankle-foot orthosis P-KAFO that incorporates a motor for powered movement assistance and an electronic brake for stance support. The system provides active assistance for knee flexion and extension during the swing phase of gait, reliable stance phase locking at any knee angle, and reliable unlocking without requiring user-generated knee or hip extension torque.
Study NCT06519721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Combined with VIC-1911
Description: Oral administration:~Lenvatinib:~Take the clinically normal dose: ≤60Kg body weight, 8mg/day; >60Kg body weight, 12mg/day;~VIC-1911:~Phase 1: Accelerated titration phase Plan to enroll 3 patients. First, enroll 1 patient, give the initial dose of VIC-1911 25mg BID, observe for 1 week, if there is no dose-limiting toxicity (DLT), increase to 50mg BID. At the same time, enroll another 2 patients, give VIC-1911 25mg BID, observe for 1 week, if no DLT, increase to 50mg BID. Observe for 2 weeks at a dose of 50mg, if no DLT occurs, continue to increase to 75mg BID, observe for 4 weeks. If no DLT occurs, continue to increase by 25mg doses, with an observation period of 4 weeks, until one case of dose-limiting toxicity or two cases of moderate toxicity occur during the titration process, then reduce to the previous dose, and determine it as the final dosing regimen.~Phase 2: Expansion phase According to the final dosing regimen selected, enroll 12 patients and observe for 3 months.
Study NCT04490096 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: [11C]-PBR28
Description: A dose of ≤ 20 mCi (approximate range for most studies is anticipated to be 5-20 mCi) of \[11C\]-PBR28 will be administered by IV injection to the patient under the direct supervision of a Nuclear Medicine Authorized User. A lesser activity may be injected if, in the opinion of a nuclear medicine authorized user complete imaging data could be generated.~Subjects will undergo an approximately 90 minute dynamic PET/CT scan over the brain starting at approximately the same time as the \[11C\]-PBR-28 injection. Scans will be acquired using a Philips PET/CT time-of-flight Ingenuity scanner (Philips Healthcare, Cleveland, OH, USA). At the end of the dynamic imaging the participant will be allowed to get off the scanner.
Study NCT03734380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laboratory-based gait retraining (LGR)
Description: Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
Study NCT03734380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-based gait retraining (SGR)
Description: Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
Study NCT03734380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise control (Ctrl)
Description: Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
Study NCT05760469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: Clinical nurse (CN) notifies research coordinator (RC) about patients with rashes. RC assesses eligibility criteria of patient based on inclusion criteria. RC provide CN with appropriate documentation tool (DT), smart device (SD), standardized red adhesive label (SRAL), and adhesive QRcode. Intervention: With written informed consent, demographic information will be collected. QRcode adhesive will be placed in the DT to track subject documentation throughout the study. Baseline live photograph (LP) of the rash will be taken with SD at day 0. LP will be taken daily. A SRAL, and a QR adhesive code will be included in the LP. LP will be automatically saved in a secure file on the cloud server under the QR code. CN will complete the DT for all rashes included in the study. Treatment of the rash will be at the discretion of the clinical team; the treatment regimen will be recorded daily. The procedure will be repeated daily for all rashes during the patient stay to a maximum of 7 days.
Study NCT06318013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: vitality test
Description: A vitality test will be performed using a vitalometer to check if the drowsiness is gone
Study NCT05241093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYML-122; cytarabine
Description: HYML-122 is administered orally consecutive with 400mg bid or 600mg bid or dose adjusted by DMC judgement in each 28-day treatment cycle. cytarabine is administered by intravenous infusion with 100mg/m2 or dose adjusted by DMC judgement once daily on the first to 7th day of each treatment cycle. Upon completion of each 28-day treatment cycle, patients may continue to receive HYML-122 and cytarabine if they are benefit from the treatment and the toxicity is tolerable.
Study NCT06342505 — intervention group
Intervention type: PROCEDURE
Intervention: Venipunctures
Description: Extra venipunctures
Study NCT04354636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver modified atraumatic restorative treatment
Description: Silver diamine fluoride that will be applied during atraumatic restorative treatment
Study NCT04354636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic restorative treatment
Description: Using atraumatic restorative treatment without applying silver diamine fluoride
Study NCT05862103 — intervention group
Intervention type: OTHER
Intervention: Treatment Strategies
Description: AMI emergency treatment process, pre-reperfusion medication, reperfusion strategy selection, and early cardiac rehabilitation after reperfusion
Study NCT06444841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital - Google Calendar
Description: Digital calendar apps allow one to digitally off-load intentions either by typing them or by speaking them (speech-to-text voice-dictation capabilities). In addition, they deliver automated reminders to perform intended tasks, either at a single time (e.g., Monday at 9 am) or at recurring times (e.g., every night at 8 pm).
Study NCT06444841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based - Memory Support System
Description: The Memory Support System is an established paper-based solution for prospective memory functioning. There is considerable evidence in the literature for its utility in mild cognitive impairment (MCI) and it has face validity to patients as supporting memory.
Study NCT04858048 — intervention group
Intervention type: PROCEDURE
Intervention: Anesthesia
Description: 2 types of anesthesia (general and WALANT) performed during the surgery
Study NCT04153396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The Treatment group
Description: The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection(betamethasone propionate 5mg and betamethasone sodium phosphate 2mg per 1ml) added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A total of 10 ml of solution will be injected into each level. The study solution will be injected into the subcutaneous tissue, paravertebral muscles, along with the posterior area around the spinous process, lamina, transverse process and the facet joints, along both sides of the planned incision. The epidural space and intrathecal space will not be infiltrated.